Solaris Resources Inc. (CVE:SLS – Get Free Report)’s share price fell 2.7% on Thursday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares changed hands during trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Stock Down 2.7%
The business has a fifty day moving average of C$6.15 and a 200-day moving average of C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Recommended Stories
- Five stocks we like better than Solaris Resources
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- Election Stocks: How Elections Affect the Stock Market
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- Trading Stocks: RSI and Why it’s Useful
- Disney’s 2026 Outlook Brightens Under Iger’s Magic Touch
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
